RxDoctor Payments Data

Charles Longo, MD

Endocrinology, Diabetes & Metabolism · Sioux Falls, SDNPI 1841266608

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $401 of the $451 with a category attached, or 88.9%. It is spread thinly across 9 manufacturers, the largest accounting for just 23.9% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in SD, where the typical reported total is $921.

$451in general payments, 2019–2025

Across 20 payments — averaging $22.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$108
  • Tepha Inc$79
  • Chiesi USA, Inc.$54
  • Pfizer$54
  • Abbott$50
  • Medtronic$45
  • plus $61 from 3 others

What the payments were for

  • Food & beverage$40189%
  • Education$5011%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$451 in reported general payments places this provider in the 30th percentile of 20 endocrinology, diabetes & metabolism providers in South Dakota.

See all endocrinology, diabetes & metabolism providers in South Dakota

Medicare billing

Part B allowed, 2024
$75,076
Medicare patients
361
Services billed
875

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide270$263,588
MounjaroTirzepatide61$69,510
Somatuline DepotLanreotide Acetate11$67,311
TrulicityDulaglutide65$64,093
ForteoTeriparatide12$48,390
JardianceEmpagliflozin77$45,806
Fiasp FlextouchInsulin Aspart (Niacinamide)54$42,169
Tresiba Flextouch U-100Insulin Degludec66$39,125
Tresiba Flextouch U-200Insulin Degludec50$35,971
Novolog FlexpenInsulin Aspart111$29,035
JanumetSitagliptin Phos/Metformin Hcl34$25,204
JanuviaSitagliptin Phosphate35$20,003
FiaspInsulin Aspart (Niacinamide)18$17,877
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/718$16,938
NovologInsulin Aspart88$14,722

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sanofi-aventis U.S. LLCLantus$16$3,72333 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 20 endocrinology, diabetes & metabolism providers in South Dakota.

Other endocrinology, diabetes & metabolism in Sioux Falls

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →